Astrazeneca plc
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$290.01B
30.9
4.54
$54.07B
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.
emptyResult
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.
Recently from Cashu
Novel serotonergic agonists: burgeoning CNS market and AstraZeneca partnership opportunities
New CNS class emerges as a commercial and pipeline opportunity Novel serotonergic agonists (NSAs) are rapidly gaining attention as a next‑generation approach to neuropsychiatric disorders, promising f…
AstraZeneca Targets Rapid‑Acting Serotonergic Therapies Through Partnerships for CNS Disorders
AstraZeneca Eyes Rapid-Acting Serotonergic Therapies AstraZeneca is positioned to engage with a fast-emerging class of novel serotonergic agonists (NSAs) that promise rapid onset and higher efficacy t…
AstraZeneca Eyes Next‑Gen Serotonergic Agonists, Partnerships to Expand CNS Pipeline
AstraZeneca stakes strategic interest in next‑generation serotonergic agonists for CNS portfolio AstraZeneca is positioning itself to benefit from the rapid industry pivot toward novel serotonergic ag…